Mexico Preclinical Cro Market Size & Outlook, 2023-2030
Mexico preclinical cro market, 2018-2030 (US$M)
Related Markets
Mexico preclinical cro market highlights
- The Mexico preclinical cro market generated a revenue of USD 65.1 million in 2023 and is expected to reach USD 104.6 million by 2030.
- The Mexico market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 65.1 million |
| Market revenue in 2030 | USD 104.6 million |
| Growth rate | 7% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.1% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 136.5 million by 2030.
Toxicology testing was the largest segment with a revenue share of 22.58% in 2023. Horizon Databook has segmented the Mexico preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is considered to be one of the most lucrative markets for R&D activities owing to the presence of skilled professionals, an increasing number of clinical research centers, and proximity to the U.S. The country provides a favorable market environment to attract R&D investment, thereby stimulating the preclinical trials outsourcing market.
The government also promotes R&D by providing cash credit for specific projects. These incentives that encourage R&D activities are expected to contribute to the preclinical trial outsourcing market growth. The country has witnessed a significant rise in investment from several global companies owing to its intellectual property system.
In addition, local and foreign investors are actively participating in the market owing to the developing country's economic growth. Moreover, the low operational cost in the country is anticipated to boost the market in Mexico.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico preclinical cro market size, by service, 2018-2030 (US$M)
Mexico Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
